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Introduction {#sec1}
============

An imbalance in mitochondrial metabolism has been implicated in the development of neovascular diseases catalyzed by aberrant angiogenesis. However, the role of heme synthesis in the development of mitochondrial dysfunction in neovascular diseases is unclear.

Neovascularization is a common phenomenon seen in vascular diseases like cancer, type 2 diabetes mellitus, proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) ([@bib14]; [@bib17]; [@bib21]; [@bib24]). Neovascularization is the disease process where new blood vessels grow from pre-existing ones, and in the eye this can contribute to ocular complications like hemorrhages, retinal detachment, and loss of central vision ([@bib6]). Endothelial cells (ECs) are key to this process, mediating different cellular functions essential for angiogenesis like proliferation, migration, and vascular permeability ([@bib48]).

We previously reported that heme synthesis inhibition is anti-angiogenic in retinal ECs *in vitro* and in animal models of ocular neovascularization. Blocking heme production in human retinal microvascular ECs (HRECs) decreased proliferation, migration, and endothelial tube formation and caused reduced protein expression of total and phosphorylated VEGF receptor 2 ([@bib4]). This antiangiogenic effect was only seen in ocular ECs, whereas ocular non-endothelial cells were not similarly affected. Heme synthesis inhibition was associated with smaller ocular neovascular lesions in choroidal and retinal neovascularization mouse models ([@bib4]; [@bib39]). However, the mechanism underlying this effect remains unknown.

The final synthesis of heme takes place in the mitochondria, when ferrochelatase (FECH) inserts ferrous ion into a precursor protoporphyrin IX (PPIX) to form protoheme (iron-protoporphyrin IX) ([@bib9]; [@bib33]; [@bib38]). By directly targeting FECH, cells can be depleted of heme and heme-containing proteins, with a concomitant buildup of PPIX ([@bib2]; [@bib50]). Apart from the role of heme in oxygen transport and storage, heme acts as a prosthetic group in many hemoprotein enzymes involved in oxidative phosphorylation, plus cytochrome P450s, catalases, and nitric oxide synthase ([@bib8]).

In the present study, we aimed to assess the relationship between mitochondrial physiology in human ECs and heme inhibition. We hypothesized that heme inhibition would lead to defects in heme-containing enzymes of the mitochondrial electron transport chain (ETC) and thus affect mitochondrial function of ECs. We show that loss of heme altered mitochondrial morphology and dynamics, causing increased reactive oxygen species (ROS) levels and depolarized membrane potential. Our studies reveal that heme synthesis is required for EC respiration and complex IV (cytochrome *c* oxidase; CcO) function specifically and can negatively impact glycolytic capacity of ECs. Thus, we characterize a previously unknown role of heme in cellular metabolism that facilitates EC function in angiogenesis.

Results {#sec2}
=======

Heme Inhibition Caused Changes to Mitochondrial Morphology and Increased Oxidative Stress {#sec2.1}
-----------------------------------------------------------------------------------------

To block heme production, we used a competitive inhibitor of FECH, the terminal enzyme responsible for catalyzing heme synthesis ([@bib44]) (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Blockade of FECH with active site inhibitor *N*-methylprotoporphyrin (NMPP) causes accumulation of precursor PPIX ([Figure S1](#mmc1){ref-type="supplementary-material"}A). HRECs treated with NMPP showed changes in mitochondrial fragmentation and shape ([Figure 1](#fig1){ref-type="fig"}A). NMPP-treated cells had decreased form factor values, indicating reduced mitochondrial branching ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B--S1G), owing to more highly fragmented mitochondria ([Figure 1](#fig1){ref-type="fig"}A, inset image). Mitochondria appeared less elongated and elliptical in NMPP-treated HRECs as seen by lower aspect ratio values ([Figure 1](#fig1){ref-type="fig"}C). To determine mitochondrial mass, we used flow cytometry and quantified median fluorescence intensity (MFI) of NMPP-treated HRECs ([@bib11]). NMPP treatment led to reduced MFI, indicating decreased mass in mitochondria ([Figure 1](#fig1){ref-type="fig"}D).Figure 1FECH Blockade Altered Mitochondrial Morphology and Increased Oxidative Stress(A--C) (A) HRECs treated with DMSO or FECH inhibitor NMPP stained with MitoTracker green (MTG). Inset images indicate magnified region marked in red boxes. Form factor (B) and aspect ratio (C) as quantified using ImageJ. Individual data points indicate mean of mitochondria analyzed from each of 12 individual cells per treatment group.(D--F) (D) Quantification of MTG fluorescence using flow cytometry and calculated median fluorescence intensity (MFI). qPCR analysis of mRNA expression under *FECH* knockdown (E) or NMPP treatment (F).(G) HRECs stained with mitoSox ROS in red and Hoechst staining in blue.(H and I) (H) Representative fluorescence peaks as measured by flow cytometry followed by (I) quantification of cells positive for red fluorescence.Bar graphs indicate mean ± SEM, n = 3. Representative results from three independent experiments. ns, non-significant, ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001, two-tailed unpaired Student\'s t test. Scale bars, 20 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

We tested mRNA levels of key mitochondrial fusion proteins involved in mitochondrial dynamics, *MFN2* and *OPA1,* and found significantly lower levels under FECH blockade conditions ([Figures 1](#fig1){ref-type="fig"}E and 1F). Fission regulator *DNM1L* (encoding Drp1) showed no change. We measured mitochondrial-specific ROS using MitoSox ROS, and cells treated with NMPP showed a marked increase in ROS levels ([Figure 1](#fig1){ref-type="fig"}G). We quantified this increase using flow cytometry and found a significant increase in MitoSox ROS-labeled HRECs treated with NMPP ([Figures 1](#fig1){ref-type="fig"}H and 1I). This effect of elevated ROS levels was also seen in RF/6A cells treated with NMPP ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). This primate cell line has properties of chorioretinal ECs ([@bib29]) and thus provides corroboration of the primary HREC data.

Loss of FECH Depolarized Mitochondrial Membrane Potential {#sec2.2}
---------------------------------------------------------

To assess mitochondrial health, we next measured membrane potential using JC-1, a polychromatic dye that on excitation forms red aggregates and green monomers depending on the energized or deenergized state of mitochondria. Both siRNA-mediated knockdown of FECH and chemical inhibition using NMPP induced loss of healthy red aggregates and an increase in monomers as seen by the green fluorescence ([Figures 2](#fig2){ref-type="fig"}A and 2D). This JC-1 excitation was quantified using flow cytometry on HRECs labeled with JC-1 dye and showed reduced red to green fluorescence ratio, indicative of mitochondrial depolarization ([Figures 2](#fig2){ref-type="fig"}B, 2C, 2E, and 2F). RF/6A cells also showed depolarized membrane potential after NMPP treatment ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4E).Figure 2Loss of FECH Reduced Mitochondrial Membrane Potential in HRECs(A--F) HRECs stained with JC-1 dye showing green monomers and red aggregates under *FECH* knockdown condition (A) and NMPP treatment (D). Representative dot plots of FL1 versus FL2 channel from three individual experiments, measuring red and green fluorescence using flow cytometry after *FECH* knockdown (B) and NMPP treatment (E). Red and green arrows indicate quadrants expressing FL1-red and FL2-green fluorescent cells. (C and F) Quantification of red:green fluorescence from flow experiment. Bar graphs indicate mean ± SEM, n = 3; ns, non-significant, ∗p \< 0.05, ∗∗∗p \< 0.001, one-way ANOVA with Tukey\'s post hoc tests. Scale bars, 20 μm. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Reduced CcO Expression and Activity Rescued by Hemin {#sec2.3}
----------------------------------------------------

To determine where heme depletion was influencing mitochondrial function, we evaluated protein complexes of the ETC after heme inhibition, as complexes II, III, and IV contain heme in their prosthetic groups ([@bib22]). FECH knockdown resulted in a significant decrease of only CcO ([Figures 3](#fig3){ref-type="fig"}A and 3B). NMPP-treated cells showed a similar decrease in CcO, and we also found increased expression of Complex V (ATP synthase) upon treatment with this small molecule ([Figures 3](#fig3){ref-type="fig"}A and 3C). Additionally, we also assessed mRNA expression of ETC complex genes, *NDUFS1* (complex I), *SDHA* (complex II), *UQCRQ* (complex III), *MT-CO1* (mitochondrially encoded CcO subunit 1), and *COX4I1* (nuclear encoded CcO subunit 1). Only the nuclear-encoded CcO gene showed a significant decrease in mRNA expression ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We then examined the protein levels of heme-containing subunit 1 of CcO (COX4I1) and found a significant decrease under both knockdown and NMPP treatment ([Figures 3](#fig3){ref-type="fig"}D--3G). Enzyme activity of CcO was also reduced, and total levels of the complex were significantly reduced after FECH blockade ([Figures 3](#fig3){ref-type="fig"}H--3K). Moreover, enzyme activities of complexes I--III remained unaffected ([Figures S5](#mmc1){ref-type="supplementary-material"}B--S5D). To confirm if our results were dependent on heme, we sought to rescue the phenotype of CcO reduction by external supplementation of heme to the cells. Hemin, a stable form of heme, was able to alleviate CcO protein expression depletion and partially rescue CcO enzyme activity ([Figures 3](#fig3){ref-type="fig"}L--3N). RF/6A cells showed a similar rescue phenotype of CcO enzyme after heme addition ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6D). We also used another heme synthesis inhibitor, succinylacetone, which blocks the second committed enzyme in heme synthesis, 5-aminolevulinic acid dehydratase (ALAD), upstream of the PPIX-FECH step ([@bib9]; [@bib49]). HRECs treated with succinylacetone showed reduction in protein expression of CcO and also Complex III ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B).Figure 3FECH Inhibition Caused Reduced CcO Expression, Rescued by Hemin(A) HRECs under *FECH* siRNA or NMPP-treated conditions were immunoblotted for Complexes I--V as indicated.(B and C) Quantification of the blots was graphed as shown relative to appropriate control.(D) *FECH* siRNA-treated HRECs were probed for CcO nuclear encoded subunit 1 (COX4I1) and FECH along with housekeeping control and (E) quantified. Similarly, HRECs treated with NMPP were blotted for CcO subunit 1 (F) with (G) quantification as shown. CcO enzyme activity was measured under *FECH* knockdown condition (H) and NMPP treatment (J) and total CcO levels were quantified by ELISA for both the conditions (I and K).(L and M) CcO protein expression and quantification under defined conditions.(N) CcO enzyme activity was partially rescued in NMPP-treated cells exposed to hemin. Immunoblot images representative from three independent experiments.Bar graphs indicate mean ± SEM, n = 3--4; ns, non-significant, ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗∗p \< 0.0001. (B, C, E, G, H--K) unpaired Student\'s t test (M and N) one-way ANOVA with Tukey\'s post hoc tests. See also [Figures S5--S7](#mmc1){ref-type="supplementary-material"}.

FECH Blockade Reduced Mitochondrial Function of Retinal ECs {#sec2.4}
-----------------------------------------------------------

To understand whether loss of function of an important complex in the ETC resulted in defects in mitochondrial respiration, we assessed maximal oxygen consumption rate (OCR) induced by the potential gradient uncoupler FCCP ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). FCCP induces uninhibited flow of electrons across the ETC, causing the enzymes of the respiratory chain to use metabolic substrates at full potential and, in turn, revealing the maximal cellular capacity that can meet energy demands under metabolically stressed conditions ([@bib12]). Under metabolic stress, both HRECs and RF/6A cells underwent increased glycolysis to meet energy demands ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2F).

Based on these optimized parameters ([Figure S3](#mmc1){ref-type="supplementary-material"}), we measured OCR of HRECs after FECH knockdown and observed reduced basal respiration ([Figures 4](#fig4){ref-type="fig"}A and 4B). Uncoupler-induced maximal respiration was significantly decreased, with a marked reduction also found in OCR-linked ATP production and spare respiratory capacity ([Figures 4](#fig4){ref-type="fig"}C--4E). Similarly, NMPP treated cells showed a dose-dependent decrease in basal ([Figures 4](#fig4){ref-type="fig"}F and 4G) and maximal respiration ([Figure 4](#fig4){ref-type="fig"}H) along with a decline in OCR-linked ATP production and spare respiratory capacity ([Figures 4](#fig4){ref-type="fig"}I and 4J). We saw a similar decrease in mitochondrial respiratory activity in RF/6A cells ([Figures S6](#mmc1){ref-type="supplementary-material"}E--S6I). Succinylacetone-treated HRECs also showed a decrease in basal and maximal respiration along with reduced OCR-linked ATP production and spare respiratory capacity ([Figures S7](#mmc1){ref-type="supplementary-material"}C--S7G).Figure 4Loss of FECH Reduced Mitochondrial Respiration(A and F) OCR kinetic traces for HRECs under *FECH* knockdown or NMPP chemical inhibition.(B and G) Basal respiration.(C and H) Maximal respiration.(D and I) OCR-linked ATP production, and (E and J) spare respiratory capacity were calculated based on OCR curves for the respective treatment group.(A and F) Representative OCR curve of three individual experiments. Bar graphs indicate mean ± SEM, n = 3; ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001 (B, C, D, and E) unpaired Student\'s t test (G, H, I, and J) one-way ANOVA with Tukey\'s post hoc tests. See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

Inhibition of FECH Led to Decreased Glycolytic Function {#sec2.5}
-------------------------------------------------------

Microvascular ECs are highly glycolytic compared with other cell types ([@bib5]). Under mitochondrial stress, both HREC and RF/6A cells had increased glycolysis over mitochondrial respiration in our system ([Figures S2](#mmc1){ref-type="supplementary-material"}C--SF). Hence, we next investigated this key cellular energetic pathway in HRECs by measuring changes in the pH of the extracellular medium. Cells were briefly starved in glucose-deficient medium, followed by induction of glycolysis using a saturating dose of glucose. Interestingly, HRECs under siRNA-mediated FECH knockdown and NMPP treatment each had decreased glycolytic capacity and glycolysis ([Figures 5](#fig5){ref-type="fig"}A--5C and 5E--5G). Both conditions depleted glycolytic reserve, as seen by a marked decrease in ECAR after 2-DG injection ([Figures 5](#fig5){ref-type="fig"}D and 5H).Figure 5FECH Inhibition Caused a Decrease in Glycolytic Function(A--H) (A and E) ECAR kinetic traces for HRECs under *FECH* knockdown or NMPP chemical inhibition. (B and F) Glycolysis, (C and G) glycolytic capacity, and (D and H) glycolytic reserve were calculated based on ECAR curves for the respective treatment group.(A and E) Representative ECAR curve of three individual experiments. Bar graphs indicate mean ± SEM, n = 3; ∗∗p \< 0.01, ∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001, unpaired Student\'s t test. 2-DG, 2-deoxyglucose.

FECH Inhibition *In Vivo* Caused Impaired Mitochondrial Energetics in Retina {#sec2.6}
----------------------------------------------------------------------------

We further determined if the effect of NMPP had the same phenotype *in vivo* in an intact eye. For this, we administered NMPP intravitreally to mice and measured OCR of retina in an *ex vivo* assay ([Figure 6](#fig6){ref-type="fig"}A). We found that retinas treated with NMPP had a significant decrease in basal respiration and a similar decline in maximal respiration ([Figures 6](#fig6){ref-type="fig"}B and 6C). Spare respiratory capacity was severely reduced in the retinas of NMPP-treated animals compared with their vehicle-treated counterparts ([Figure 6](#fig6){ref-type="fig"}D). We also observed about a 30% reduction in protein expression of subunit 1 of CcO in the NMPP-treated retinas ([Figures 6](#fig6){ref-type="fig"}E and 6F).Figure 6FECH Inhibition *In Vivo* Decreased Mitochondrial Respiration in Retina(A) Representative OCR kinetic traces for retina from animals treated with NMPP.(B--D) (B) Basal respiration, (C) maximal respiration, and (D) spare respiratory capacity were calculated based on OCR curves for the respective treatment groups.(E) Immunoblot showing CcO nuclear encoded subunit 1 (COX4I1) protein expression from three pooled retinal tissue lysates from NMPP treated eyes and (F) quantification of immunoblots. Graphs indicate mean ± SEM for two tissue punches from each retina per treatment group, n = 6--7 per treatment condition. ∗p \< 0.05, ∗∗∗p \< 0.001, unpaired Student\'s t test.

Discussion {#sec3}
==========

Heme synthesis blockade suppresses pathological angiogenesis by poorly understood mechanisms. In the present study, we sought to investigate the effects of heme inhibition on the mitochondrial function of retinal ECs by directly studying heme-containing complexes of the ETC and documenting mitochondrial physiology under heme depletion.

The mitochondrial ETC is a major source of ROS induced by vascular endothelial growth factor (VEGF) in hyperglycemic and hypoxic cellular environments ([@bib7]; [@bib35]; [@bib51]). In PDR, increased mitochondrial ROS and impaired Ca^2+^ signaling can cause an increase in oxidative stress ([@bib25]; [@bib34]; [@bib47]; [@bib51]). Complex III of the ETC was recently shown to be important for umbilical vein EC respiration and thus proliferation during angiogenesis ([@bib10]). Mitochondrial dysfunction in the retinal pigment epithelium and photoreceptors has been reported for wet AMD ([@bib3]; [@bib27]), but evidence in retinal ECs is limited. Metabolic factors like succinate and adenosine, generated from the Krebs cycle and ATP metabolism, respectively, are proangiogenic for hypoxia-driven neovascularization ([@bib43]). However, the exact mechanism of how metabolites disrupt mitochondrial energetics in ischemic retinal ECs remains unclear ([@bib15]; [@bib42]).

Mitochondrial dysfunction in ECs leads to pathological angiogenesis. Heme and heme-containing enzymes play a significant role in this process, but the linkage between these phenomena has not been extensively explored. Serine synthesis deficiency induced heme depletion in ECs and caused decreased mitochondrial respiration and multiorgan angiogenic defects in animals ([@bib49]), whereas heme accumulation in ECs due to an altered heme exporter affects angiogenesis and causes endoplasmic reticulum stress ([@bib36]). Apart from ECs, non-small cell lung carcinoma cells with elevated heme synthesis levels had increases in enzyme activities of the ETC. Increased production of heme was associated with increased migratory and invasive properties of these cells and xenograft tumors in mice ([@bib46]). Here, we demonstrated how heme depletion by blockade of the terminal synthesis enzyme FECH led to defects in CcO and ETC disruption ([Figure 7](#fig7){ref-type="fig"}). Retinal and choroidal ECs alike have increased mitochondrial-specific oxidative stress, dysfunctional mitochondrial physiology, and disruption of glycolysis as a result of these defects.Figure 7Schematic Model of Mitochondrial Dysfunction on Heme LossHeme synthesis begins with the condensation of glycine and succinyl CoA in the mitochondrial matrix. The final step is the insertion of ferrous ion into protoporphyrin IX (PPIX), catalyzed by ferrochelatase (FECH) to produce protoheme (also known as heme b). Protoheme and its derivatives are available for different cellular enzymes, including complexes of the ETC (e, electrons). Heme *a* is synthesized by sub-hemylation steps and utilized by CcO (Complex IV) for composition of the holoenzyme. Heme synthesis blockade by inhibiting the terminal synthesis enzyme FECH leads to CcO defects and disrupts cellular energetics. Mitochondrial dynamics is altered with reduced fusion and mass, depolarized membrane potential (ΔΨ~m~) and elevated reactive oxygen species (ROS).

Changes to mitochondrial morphology can indicate alterations in mitochondrial dynamics and cellular function. Our findings of reduced form factor and aspect ratio after FECH blockade indicate greater fragmentation and decreased length ([@bib13]; [@bib37]). Furthermore, reduced mitochondrial mass was evident by our flow cytometric analysis. HRECs after heme depletion also had reduced *MFN2* and *OPA1* transcript levels. Reduction of these mitochondrial fusion protein marker genes confirms a change in mitochondrial dynamics. An increase in fragmented mitochondria also leads to increased ROS levels ([@bib19]), as confirmed by our results. Moreover, disruption of fusion proteins can also lead to an increase in ROS levels ([@bib23]), as also evident in our cell model. Although we did not observe any change in fission protein expression, decreased *MFN2* is also consistent with the smaller, fragmented mitochondria we observed, similar to those seen in diabetic mouse coronary ECs ([@bib31]).

Inner mitochondrial membrane potential (ΔΨ~m~) was considerably decreased after FECH knockdown or NMPP treatment. This finding was explained by our result of reduced CcO expression and activity, which might have collapsed the potential gradient and caused a reduced membrane potential. Our mitochondrial energetics findings further support this result. A significant reduction in FCCP-induced maximal respiration indicates defective CcO, which is unable to perform the role of electron transfer. Uncoupling brought on by FCCP causes the ETC to rely on CcO to carry out oxidative phosphorylation by the free-flowing electrons ([@bib12]). Under FECH inhibition conditions, FCCP-induced maximal respiration was affected, indicating CcO dysfunction due to heme loss.

Heme depletion by directly blocking FECH primarily affected levels and activity of CcO of all the other heme-containing complexes of the ETC in ECs of the retina and choroid. CcO subunit 1 contains heme *a* and *a*~3~ (not found in complexes I--III and V). Heme *a* is made in a series of sub-synthesis hemylation steps carried out by heme *a* synthase and is essential for proper folding and stability of CcO ([@bib22]) ([Figure 7](#fig7){ref-type="fig"}). CcO is particularly sensitive to FECH inhibition-induced heme depletion, possibly affecting the hemylation process downstream of protoheme synthesis, leading to a smaller pool of heme *a* ([@bib2]; [@bib45]). COX10 and COX15, proteins responsible for conversion of heme *b* (synthesized by FECH) to heme *a* were among the top-scoring genes that caused ETC disruption after heme depletion in acute myeloid leukemia cells ([@bib28]), further suggesting the significance of heme *a* supply as a mediator of mitochondrial function, since it is a prosthetic group specifically in CcO holoenzyme. Furthermore, blocking the skeletal muscle-specific subunit 7a of CcO decreased mitochondrial ATP production in mouse hindlimb muscles. Interestingly, this was associated with reduced muscle angiogenesis and decreased capillarity ([@bib26]), further supporting a link between CcO and EC function. Our findings on the mRNA and protein levels plus enzyme activities of all ETC complexes are consistent with this hypothesis that FECH inhibition preferentially disrupts CcO expression and function.

Loss of functional CcO was restored at least partially by extracellular heme supplementation. Additionally, blocking heme synthesis upstream of FECH by using succinylacetone also led to a similar mitochondrial phenotype as FECH blockade. This suggests that the EC phenotype after FECH inhibition is heme dependent and not due to an off-target effect of NMPP or due to PPIX buildup/toxicity ([@bib54]). NMPP caused significant overexpression of complex V (not seen under FECH knockdown), which could be a secondary effect of damage to CcO, causing compensatory upregulation of ATP synthase ([@bib16]; [@bib41]). Notably, succinylacetone produced a decrease in both Complex III and CcO, perhaps due to a more profound heme synthesis blockade than that achieved by FECH inhibition or knockdown. Our studies previously reported effects of NMPP and FECH knockdown specific to ECs of retina, choroid, brain, and umbilical vein, and we did not observe a similar anti-proliferative phenotype on FECH blockade in other ocular cell types of non-endothelial origin ([@bib4]). However, the phenotype of FECH deficiency on ETC complexes in other cell types beyond ECs would be an interesting aspect for future exploration.

Perhaps non-endothelial cell types can meet their energy demands from the glycolysis pathway in the event of heme depletion-induced ETC dysfunction ([@bib40]). Conversely, loss of mitochondrial respiration in ECs due to lack of functional oxidative phosphorylation did not result in compensation by the glycolysis pathway in ECs ([@bib55]). ECs rely upon aerobic glycolysis for nearly 85% of their energy, a feature that is highly active during aberrant angiogenesis ([@bib5]). Severe heme depletion could possibly disrupt NADH/H^+^ and redox homeostasis, as already evident from ETC dysfunction. Moreover, increased ROS levels in ECs can shift their metabolic needs to accommodate cellular damage and dysfunction, in which case both cellular energetic systems are collapsed ([@bib49]; [@bib52]; [@bib53]). Interestingly, mitochondrial transcription of CcO subunit 1 (*MT-CO1*) mRNA is not affected after heme loss (although protein levels were decreased), but the nuclear encoded CcO gene *COX4I1* was significantly decreased at both the mRNA and protein levels after FECH inhibition. This is in keeping with heme acting at the post-transcriptional level to stabilize the assembly of the CcO subunits with minimal effect on CcO mitochondrial transcription itself.

In summary, our findings provide a previously unidentified link between heme synthesis, angiogenesis, and mitochondrial energetics. Specifically, heme synthesis blockade via FECH leads to a reduction in heme availability for hemoprotein components of the ETC, notably CcO, likely due to a shortage of heme *a* and *a*~3~. This is then associated with reduced oxidative phosphorylation, with concomitant loss of mitochondrial membrane potential and changes in mitochondrial shape and dynamics, as well as increased ROS production ([Figure 7](#fig7){ref-type="fig"}). Blockade of heme during the early stages of the pathway (via ALAD) disrupts heme *b* synthesis, affecting the ETC proteins beyond just Complex IV. This potentially explains how ECs rely on a constant supply of heme during increased energy demands, essential for the formation of neovessels. The role of heme synthesis in mitochondrial function and pathological angiogenesis has been overlooked. Our observations bridge this gap in knowledge by characterizing the metabolic phenotype of ECs under heme deficiency. Loss of heme provokes prominent anti-angiogenic effects that might be exploited therapeutically for neovascular eye disease. Our findings invite future studies to further our understanding of metabolic dysfunction in neovascularization.

Limitations of the Study {#sec3.1}
------------------------

Retinal ECs are technically laborious for experimental manipulations. Apart from being difficult to transfect, low absolute heme levels precluded spectral determination of hemes *a*, *b*, and *c*. NMPP as a FECH inhibitor could be deleterious to other hemoproteins in ECs and could have off-target effects, although we titrated NMPP to well below toxic levels in these studies and complemented NMPP findings with a knockdown approach and succinylacetone treatment. Similarly, using hemin to rescue FECH inhibition-induced heme depletion has limitations. Hemin itself can introduce mitochondrial toxicity ([@bib18]), and complete rescue of ETC damage through hemin supplementation is challenging. Additionally, damage to CcO due to insufficient heme could impair formation of ETC supercomplexes ([@bib1]), which was not assessed in our study. Resolving mitochondrial lysates isolated from NMPP-treated ECs in their endogenous form, for example, by a native gel electrophoresis method, could identify disruption to the assembly of these complexes ([@bib20]).

We previously tested a genetic mouse model with a M98K point mutation in the *Fech* gene (*Fech*^m1Pas^) leading to deficiency in FECH activity and found reduced neovascular lesions in the eye ([@bib4]; [@bib39]). This *Fech*^m1Pas^ mouse model shows pronounced PPIX buildup and *increased* mitochondrial respiratory activity, specifically CcO ([@bib32]), likely a compensatory response to constitutive heme depletion. This renders them problematic for corroborating our findings *in vivo*. Moreover, complete loss of function of FECH is incompatible with survival ([@bib30]). For these reasons, for *in vivo* validation we employed here an acute model of FECH blockade using local administration of NMPP intravitreally. Nonetheless, this FECH inhibition *in vivo* had energetic effects in the retina similar to those seen on retinal and choroidal ECs cultured *in vitro*. However, an important limitation is that this technique cannot distinguish the energetic profiles of ECs from other cell types present in the retina.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Timothy W. Corson (<tcorson@iu.edu>).

### Materials Availability {#sec3.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec3.2.3}

The published article includes all datasets generated or analyzed during this study.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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